Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q2 2024 Earnings Call Transcript

So, it’s hard to sort of say, what would be differentiated. But I can tell you what our program is looking to achieve and that would be something that is able to be dosed QD orally, something that is very potent against KIT, but selective. And so, leading to a good safety profile and just balancing that potency and selectivity, so that the efficacy and safety profile could potentially be something that you would have as best-in-class. And then I would just say that the oral inhibitors may be more tunable. I think this is something that remains to be proven in the clinic but whether they’re able to be dosed and tuned more finely than a monoclonal antibody, you can certainly have a little bit more flexibility over that. So, I think it remains to be determined, but one potential strategy as well.

Jay Olson: Okay, great. Thank you. And then can you just talk about how you’re thinking about additional indications in your development plan beyond CSU?

Tara Kieffer: Sure. You mean for the KIT inhibitor?

Jay Olson: Yes.

Tara Kieffer: Yes. The reason that we’re interested in KIT is it obviously is a key driver, for mass cells. We know that mass cells have been implicated in a number of different indications. So, certainly, chronic inducible urticaria or CIndU is something that’s also been studied with this target. There’s some good data from the monoclonal antibodies here. EoE or eosinophilic esophagitis is also another indication we’d be interested in. PN as well and even potentially asthma is something that one could think about with these types of inhibitors.

Operator: Thank you. And I am showing no further questions. I would now like to turn the call back over to Jennifer Viera for closing remarks.

Jennifer Viera: Thank you, operator, and thanks to everyone for joining us today. If you have additional questions, please feel free to contact us by e-mail or call the office. Have a great night.

Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect.